Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-NIS in Malignant Peripheral Nerve Sheath Tumor
NCT02700230Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2017
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MV-NIS in malignant peripheral nerve sheath tumor (MPNST), sponsored by Mayo Clinic. Primary endpoints: Best response using the World Health Organization response criteria up to 2 years, Incidence of adverse events according to CTCAE v4.0 up to 2 years and 1 more. Started Mar 2017; status: completed.
02
Drugs
MV-NIS
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02700230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700230.